Ruben A. Mesa, MD, FACP, moderates this discussion with Rafael Bejar, MD, PhD; Elias Jabbour, MD; and Rami Komrokji, MD. These experts in hematology and oncology discuss the pathways involved in leukemic transformation, risk-adjusted approaches to treatment, and supportive care in acute myeloid leukemia.
In this segment, Ruben A. Mesa, MD, FACP; Rami Komrokji, MD; Elias Jabbour, MD; and Rafael Bejar, MD, PhD, emphasize the importance of involving a multidisciplinary team in the management of acute myeloid leukemia (AML).
A multidisciplinary approach to acute myeloid leukemia (AML) is key for management, says Rami Komrokji, MD. At Komrokji’s institution, nurses are familiar with the signs of complication and infection and treat leukemia at all times. Members of the hematological service work hand in hand with infectious disease colleagues, oftentimes following and discussing patients together. Palliative and pain services, nutrition, and transplant teams are also frequently involved in the management of patients with leukemia. Treating patients in the hands of experts of a multidisciplinary team is essential, notes Elias Jabbour, MD.
This is currently an exciting time for AML, states Rafael Bejar, MD, PhD. Several promising therapies are under investigation, such as novel immune therapies. It is also important to maximize the benefit of currently available treatments, adds Komrokji, including refining best supportive care practices.